title: Exacerbation of ischemic dysfunction by angiotensin II in red cell-perfused rabbit hearts. Effects on coronary flow, contractility, and high-energy phosphate metabolism.
abstract: We studied the effects of angiotensin II during low-flow ischemia and reperfusion using red cell-perfused isovolumic rabbit hearts. Under baseline conditions where coronary perfusion pressure (CPP) was 100 mm Hg and left ventricular end-diastolic pressure (LVEDP) was set at 10 mm Hg, 10(-8) M angiotensin II caused a mild increase in LV developed pressure (+12%) and decrease in coronary flow (-8%). Low-flow ischemia was imposed by reducing CPP to 15 mm Hg for 30 min followed by 30 min of reperfusion. During ischemia, the angiotensin II group showed a gradual further reduction in coronary flow in association with a greater depression of LV developed pressure and increase in LVEDP relative to the no-drug group. To separate the effect of angiotensin II on coronary flow from a direct myocardial effect, the angiotensin II group was compared with an additional no-drug group with a matched progressive reduction in coronary flow during ischemia. In these groups, the ischemic depression of LV developed pressure, myocardial ATP levels, and lactate production were similar. However, the ischemic rise in LVEDP was greater (42.0 +/- 5.4 vs. 19.9 +/- 1.3 mm Hg, P less than 0.01) and recovery was incomplete in the angiotensin II group. These observations suggest that angiotensin II exerts a direct adverse effect on LV diastolic relaxation during low-flow ischemia and recovery.
authors.affiliation: Charles A. Dana Research Institute, Beth Israel Hospital, Boston, massachusetts.
authors.forename: T
authors.initials: T
authors.lastname: Mochizuki
authors.forename: F R
authors.initials: FR
authors.lastname: Eberli
authors.forename: C S
authors.initials: CS
authors.lastname: Apstein
authors.forename: B H
authors.initials: BH
authors.lastname: Lorell
mesh_terms: D000255:Adenosine Triphosphate / Q000032:analysis; D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D003326:Coronary Circulation / Q000187:drug effects*; D003327:Coronary Disease / Q000503:physiopathology*; D004734:Energy Metabolism / Q000187:drug effects*; D004912:Erythrocytes / Q000502:physiology; D066298:In Vitro Techniques; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D015425:Myocardial Reperfusion; D010710:Phosphates / Q000378:metabolism*; D010725:Phosphocreatine / Q000032:analysis; D011817:Rabbits
chemical_list: D010710:Phosphates; D010725:Phosphocreatine; D000804:Angiotensin II; D000255:Adenosine Triphosphate; D002118:Calcium